drugset

drugset / Trial / NCT00354146

A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia.

NCT00354146 ↗

Phase 2 Completed 252 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effectiveness (response rate) and safety of tipifarnib in patients with refractory or relapsed AML.

Timeline

Start: 2001-04
Primary completion: —
Completion: 2003-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	tipifarnib	Small molecule	600 mg	Oral

Indications